Author's response to Letter to the Editor: Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis

Comment

David E Klein et al. J Stroke Cerebrovasc Dis. 2020 Dec.

. 2020 Dec;29(12):105227.

doi: 10.1016/j.jstrokecerebrovasdis.2020.105227. Epub 2020 Jul 31.

No abstract available

Comment on

Cerebral venous thrombosis: A typical presentation of COVID-19 in the young.
Klein DE, Libman R, Kirsch C, Arora R. Klein DE, et al. J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104989. doi: 10.1016/j.jstrokecerebrovasdis.2020.104989. Epub 2020 May 23. J Stroke Cerebrovasc Dis. 2020. PMID: 32689590 Free PMC article.

1. Siang KC, Zalhan AF, Hasan SS. Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis. J. Stroke Cerebrovasc Dis. 2020 - PMC - PubMed
1. Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017;2(2) CD001100. - PMC - PubMed
1. Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol. 2012;19(7):1030–1036. - PubMed
1. Coutinho JM, Ferro JM, Canhão P. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke. 2010;41(11):2575–2580. - PubMed
1. Masuhr F, Einhaupl K. Treatment of cerebral venous and sinus thrombus. In: Caso V, Angelli G, Paciaroni M, editors. Handbook on Cerebral Venous Thrombosis. Karger Publishers; San Ramon, CA: 2008. pp. 132–143.